A Phase I Clinical Study and <i>In Vivo</i> Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma
These results suggest a lack of cross-resistance with the standard of care and support the translational value of the Vk*MYC model system. Further clinical investigation of PT-112 is warranted in multiple myeloma.
Authors
- J. Jimeno (ORCID: https://orcid.org/0009-0000-0279-8763)
- P. Leif Bergsagel (ORCID: https://orcid.org/0000-0003-1523-7388)
- Marta Chesi (ORCID: https://orcid.org/0000-0002-4024-8225)
- Matthew R. Price (ORCID: https://orcid.org/0000-0002-3769-737X)
- Sarah E. Gibson (ORCID: https://orcid.org/0000-0003-2427-6442)
- Dan T. Vogl (ORCID: https://orcid.org/0000-0002-2935-2566)
- Sikander Ailawadhi (ORCID: https://orcid.org/0000-0002-8377-8111)
- Christina Y. Yim (ORCID: https://orcid.org/0009-0004-2784-1528)
- Meaghen E. Sharik (ORCID: https://orcid.org/0009-0004-3128-4517)
- Taxiarchis Kourelis (ORCID: https://orcid.org/0000-0001-8573-9434)
- Tyler D. Ames (ORCID: https://orcid.org/0000-0002-1124-5236)
- Megan T. Du (ORCID: https://orcid.org/0000-0003-0486-4837)
- Johan Baeck (ORCID: https://orcid.org/0009-0007-6188-0565)
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
- Io Therapeutics (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2574
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00